CommentDefinition and management of radioactive iodine-refractory differentiated thyroid cancer
References (10)
- et al.
Progress in molecular-based management of differentiated thyroid cancer
Lancet
(2013) - et al.
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy
J Clin Endocrinol Metab
(2006) - et al.
Clinical outcomes following empiric radioiodine therapy in patients with structurally identifiable metastatic follicular cell-derived thyroid carcinoma with negative diagnostic but positive post-therapy 131I whole-body scans
Thyroid
(2012) - et al.
Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software
J Nucl Med
(2004) - et al.
Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning
J Clin Endocrinol Metab
(2006)
There are more references available in the full text version of this article.
Cited by (263)
Molecular mechanisms underlying sodium iodide symporter expression at the plasma membrane in the thyroid follicular cell
2023, Current Opinion in Endocrine and Metabolic ResearchRole of albumin Cys34 redox state in the progression of differentiated thyroid carcinoma and induction of ferroptosis
2023, Free Radical Biology and MedicineMolecular basis and targeted therapy in thyroid cancer: Progress and opportunities
2023, Biochimica et Biophysica Acta - Reviews on CancerInflammatory tumor microenvironment of thyroid cancer promotes cellular dedifferentiation and silencing of iodide-handling genes expression
2023, Pathology Research and PracticeRadioiodine therapy in advanced differentiated thyroid cancer: Resistance and overcoming strategy
2023, Drug Resistance UpdatesHLA-restricted Epitopes Prediction of Papillary Thyroid Carcinoma
2024, Research Square
Copyright © 2014 Elsevier Ltd. All rights reserved.